1
|
Luo Y, Kusay AS, Jiang T, Chebib M, Balle T. Delta-containing GABA A receptors in pain management: Promising targets for novel analgesics. Neuropharmacology 2021; 195:108675. [PMID: 34153311 DOI: 10.1016/j.neuropharm.2021.108675] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/20/2020] [Revised: 06/01/2021] [Accepted: 06/11/2021] [Indexed: 12/26/2022]
Abstract
Communication between nerve cells depends on the balance between excitatory and inhibitory circuits. GABA, the major inhibitory neurotransmitter, regulates this balance and insufficient GABAergic activity is associated with numerous neuropathological disorders including pain. Of the various GABAA receptor subtypes, the δ-containing receptors are particularly interesting drug targets in management of chronic pain. These receptors are pentameric ligand-gated ion channels composed of α, β and δ subunits and can be activated by ambient levels of GABA to generate tonic conductance. However, only a few ligands preferentially targeting δ-containing GABAA receptors have so far been identified, limiting both pharmacological understanding and drug-discovery efforts, and more importantly, understanding of how they affect pain pathways. Here, we systemically review and discuss the known drugs and ligands with analgesic potential targeting δ-containing GABAA receptors and further integrate the biochemical nature of the receptors with clinical perspectives in pain that might generate interest among researchers and clinical physicians to encourage analgesic discovery efforts leading to more efficient therapies.
Collapse
Affiliation(s)
- Yujia Luo
- Sydney Pharmacy School, Faculty of Medicine and Health, The University of Sydney, NSW, 2006, Australia; Brain and Mind Centre, The University of Sydney, Camperdown, NSW, 2050, Australia
| | - Ali Saad Kusay
- Sydney Pharmacy School, Faculty of Medicine and Health, The University of Sydney, NSW, 2006, Australia; Brain and Mind Centre, The University of Sydney, Camperdown, NSW, 2050, Australia
| | - Tian Jiang
- Sydney Pharmacy School, Faculty of Medicine and Health, The University of Sydney, NSW, 2006, Australia; Brain and Mind Centre, The University of Sydney, Camperdown, NSW, 2050, Australia
| | - Mary Chebib
- Sydney Pharmacy School, Faculty of Medicine and Health, The University of Sydney, NSW, 2006, Australia; Brain and Mind Centre, The University of Sydney, Camperdown, NSW, 2050, Australia
| | - Thomas Balle
- Sydney Pharmacy School, Faculty of Medicine and Health, The University of Sydney, NSW, 2006, Australia; Brain and Mind Centre, The University of Sydney, Camperdown, NSW, 2050, Australia.
| |
Collapse
|
2
|
Prevost MS, Bouchenaki H, Barilone N, Gielen M, Corringer PJ. Concatemers to re-investigate the role of α5 in α4β2 nicotinic receptors. Cell Mol Life Sci 2021; 78:1051-1064. [PMID: 32472188 PMCID: PMC11071962 DOI: 10.1007/s00018-020-03558-z] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/22/2019] [Revised: 05/15/2020] [Accepted: 05/22/2020] [Indexed: 01/08/2023]
Abstract
Nicotinic acetylcholine receptors (nAChRs) are pentameric ion channels expressed in the central nervous systems. nAChRs containing the α4, β2 and α5 subunits are specifically involved in addictive processes, but their functional architecture is poorly understood due to the intricacy of assembly of these subunits. Here we constrained the subunit assembly by designing fully concatenated human α4β2 and α4β2α5 receptors and characterized their properties by two-electrodes voltage-clamp electrophysiology in Xenopus oocytes. We found that α5-containing nAChRs are irreversibly blocked by methanethiosulfonate (MTS) reagents through a covalent reaction with a cysteine present only in α5. MTS-block experiments establish that the concatemers are expressed in intact form at the oocyte surface, but that reconstitution of nAChRs from loose subunits show inefficient and highly variable assembly of α5 with α4 and β2. Mutational analysis shows that the concatemers assemble both in clockwise and anticlockwise orientations, and that α5 does not contribute to ACh binding from its principal (+) site. Reinvestigation of suspected α5-ligands such as galantamine show no specific effect on α5-containing concatemers. Analysis of the α5-D398N mutation that is linked to smoking and lung cancer shows no significant effect on the electrophysiological function, suggesting that its effect might arise from alteration of other cellular processes. The concatemeric strategy provides a well-characterized platform for mechanistic analysis and screening of human α5-specific ligands.
Collapse
Affiliation(s)
- Marie S Prevost
- Unité Récepteurs-Canaux, Institut Pasteur, UMR 3571, CNRS, 75015, Paris, France
| | - Hichem Bouchenaki
- Unité Récepteurs-Canaux, Institut Pasteur, UMR 3571, CNRS, 75015, Paris, France
| | - Nathalie Barilone
- Unité Récepteurs-Canaux, Institut Pasteur, UMR 3571, CNRS, 75015, Paris, France
| | - Marc Gielen
- Unité Récepteurs-Canaux, Institut Pasteur, UMR 3571, CNRS, 75015, Paris, France.
- Sorbonne Université, 21, rue de l'école de médecine, 75006, Paris, France.
| | | |
Collapse
|
3
|
Stefanits H, Milenkovic I, Mahr N, Pataraia E, Baumgartner C, Hainfellner JA, Kovacs GG, Kasprian G, Sieghart W, Yilmazer-Hanke D, Czech T. Alterations in GABAA Receptor Subunit Expression in the Amygdala and Entorhinal Cortex in Human Temporal Lobe Epilepsy. J Neuropathol Exp Neurol 2020; 78:1022-1048. [PMID: 31631219 DOI: 10.1093/jnen/nlz085] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/19/2019] [Revised: 07/06/2019] [Indexed: 12/14/2022] Open
Abstract
The amygdala has long been implicated in the pathophysiology of human temporal lobe epilepsy (TLE). The different nuclei of this complex structure are interconnected and share reciprocal connections with the hippocampus and other brain structures, partly via the entorhinal cortex. Expression of GABAA receptor subunits α1, α2, α3, α5, β2, β2/3, and γ2 was evaluated by immunohistochemistry in amygdala specimens and the entorhinal cortex of 12 TLE patients and 12 autopsy controls. A substantial decrease in the expression of α1, α2, α3, and β2/3 subunits was found in TLE cases, accompanied by an increase of γ2 subunit expression in many nuclei. In the entorhinal cortex, the expression of all GABAA receptor subunits was decreased except for the α1 subunit, which was increased on cellular somata. The overall reduction in α subunit expression may lead to decreased sensitivity to GABA and its ligands and compromise phasic inhibition, whereas upregulation of the γ2 subunit might influence clustering and kinetics of receptors and impair tonic inhibition. The description of these alterations in the human amygdala is important for the understanding of network changes in TLE as well as the development of subunit-specific therapeutic agents for the treatment of this disease.
Collapse
Affiliation(s)
- Harald Stefanits
- Department of Neurosurgery, Institute of Neurology, Department of Neurology, Department of Biomedical Imaging and Image Guided Therapy, Center for Brain Research, Department of Molecular Neurosciences, Medical University of Vienna, Vienna, Austria; Second Neurological Department, General Hospital Hietzing, Vienna, Austria; and Clinical Neuroanatomy, Neurology Department, Medical Faculty, Ulm University, Ulm, Germany
| | - Ivan Milenkovic
- Department of Neurosurgery, Institute of Neurology, Department of Neurology, Department of Biomedical Imaging and Image Guided Therapy, Center for Brain Research, Department of Molecular Neurosciences, Medical University of Vienna, Vienna, Austria; Second Neurological Department, General Hospital Hietzing, Vienna, Austria; and Clinical Neuroanatomy, Neurology Department, Medical Faculty, Ulm University, Ulm, Germany
| | - Nina Mahr
- Department of Neurosurgery, Institute of Neurology, Department of Neurology, Department of Biomedical Imaging and Image Guided Therapy, Center for Brain Research, Department of Molecular Neurosciences, Medical University of Vienna, Vienna, Austria; Second Neurological Department, General Hospital Hietzing, Vienna, Austria; and Clinical Neuroanatomy, Neurology Department, Medical Faculty, Ulm University, Ulm, Germany
| | - Ekaterina Pataraia
- Department of Neurosurgery, Institute of Neurology, Department of Neurology, Department of Biomedical Imaging and Image Guided Therapy, Center for Brain Research, Department of Molecular Neurosciences, Medical University of Vienna, Vienna, Austria; Second Neurological Department, General Hospital Hietzing, Vienna, Austria; and Clinical Neuroanatomy, Neurology Department, Medical Faculty, Ulm University, Ulm, Germany
| | - Christoph Baumgartner
- Department of Neurosurgery, Institute of Neurology, Department of Neurology, Department of Biomedical Imaging and Image Guided Therapy, Center for Brain Research, Department of Molecular Neurosciences, Medical University of Vienna, Vienna, Austria; Second Neurological Department, General Hospital Hietzing, Vienna, Austria; and Clinical Neuroanatomy, Neurology Department, Medical Faculty, Ulm University, Ulm, Germany
| | - Johannes A Hainfellner
- Department of Neurosurgery, Institute of Neurology, Department of Neurology, Department of Biomedical Imaging and Image Guided Therapy, Center for Brain Research, Department of Molecular Neurosciences, Medical University of Vienna, Vienna, Austria; Second Neurological Department, General Hospital Hietzing, Vienna, Austria; and Clinical Neuroanatomy, Neurology Department, Medical Faculty, Ulm University, Ulm, Germany
| | - Gabor G Kovacs
- Department of Neurosurgery, Institute of Neurology, Department of Neurology, Department of Biomedical Imaging and Image Guided Therapy, Center for Brain Research, Department of Molecular Neurosciences, Medical University of Vienna, Vienna, Austria; Second Neurological Department, General Hospital Hietzing, Vienna, Austria; and Clinical Neuroanatomy, Neurology Department, Medical Faculty, Ulm University, Ulm, Germany
| | - Gregor Kasprian
- Department of Neurosurgery, Institute of Neurology, Department of Neurology, Department of Biomedical Imaging and Image Guided Therapy, Center for Brain Research, Department of Molecular Neurosciences, Medical University of Vienna, Vienna, Austria; Second Neurological Department, General Hospital Hietzing, Vienna, Austria; and Clinical Neuroanatomy, Neurology Department, Medical Faculty, Ulm University, Ulm, Germany
| | - Werner Sieghart
- Department of Neurosurgery, Institute of Neurology, Department of Neurology, Department of Biomedical Imaging and Image Guided Therapy, Center for Brain Research, Department of Molecular Neurosciences, Medical University of Vienna, Vienna, Austria; Second Neurological Department, General Hospital Hietzing, Vienna, Austria; and Clinical Neuroanatomy, Neurology Department, Medical Faculty, Ulm University, Ulm, Germany
| | - Deniz Yilmazer-Hanke
- Department of Neurosurgery, Institute of Neurology, Department of Neurology, Department of Biomedical Imaging and Image Guided Therapy, Center for Brain Research, Department of Molecular Neurosciences, Medical University of Vienna, Vienna, Austria; Second Neurological Department, General Hospital Hietzing, Vienna, Austria; and Clinical Neuroanatomy, Neurology Department, Medical Faculty, Ulm University, Ulm, Germany
| | - Thomas Czech
- Department of Neurosurgery, Institute of Neurology, Department of Neurology, Department of Biomedical Imaging and Image Guided Therapy, Center for Brain Research, Department of Molecular Neurosciences, Medical University of Vienna, Vienna, Austria; Second Neurological Department, General Hospital Hietzing, Vienna, Austria; and Clinical Neuroanatomy, Neurology Department, Medical Faculty, Ulm University, Ulm, Germany
| |
Collapse
|
4
|
Anderson LL, Absalom NL, Abelev SV, Low IK, Doohan PT, Martin LJ, Chebib M, McGregor IS, Arnold JC. Coadministered cannabidiol and clobazam: Preclinical evidence for both pharmacodynamic and pharmacokinetic interactions. Epilepsia 2019; 60:2224-2234. [PMID: 31625159 PMCID: PMC6900043 DOI: 10.1111/epi.16355] [Citation(s) in RCA: 96] [Impact Index Per Article: 19.2] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/24/2019] [Revised: 09/05/2019] [Accepted: 09/09/2019] [Indexed: 12/25/2022]
Abstract
OBJECTIVE Cannabidiol (CBD) has been approved by the US Food and Drug Administration (FDA) to treat intractable childhood epilepsies, such as Dravet syndrome and Lennox-Gastaut syndrome. However, the intrinsic anticonvulsant activity of CBD has been questioned due to a pharmacokinetic interaction between CBD and a first-line medication, clobazam. This recognized interaction has led to speculation that the anticonvulsant efficacy of CBD may simply reflect CBD augmenting clobazam exposure. The present study aimed to address the nature of the interaction between CBD and clobazam. METHODS We examined whether CBD inhibits human CYP3A4 and CYP2C19 mediated metabolism of clobazam and N-desmethylclobazam (N-CLB), respectively, and performed studies assessing the effects of CBD on brain and plasma pharmacokinetics of clobazam in mice. We then used the Scn1a+/- mouse model of Dravet syndrome to examine how CBD and clobazam interact. We compared anticonvulsant effects of CBD-clobazam combination therapy to monotherapy against thermally-induced seizures, spontaneous seizures and mortality in Scn1a+/- mice. In addition, we used Xenopus oocytes expressing γ-aminobutyric acid (GABA)A receptors to investigate the activity of GABAA receptors when treated with CBD and clobazam together. RESULTS CBD potently inhibited CYP3A4 mediated metabolism of clobazam and CYP2C19 mediated metabolism of N-CLB. Combination CBD-clobazam treatment resulted in greater anticonvulsant efficacy in Scn1a+/- mice, but only when an anticonvulsant dose of CBD was used. It is important to note that a sub-anticonvulsant dose of CBD did not promote greater anticonvulsant effects despite increasing plasma clobazam concentrations. In addition, we delineated a novel pharmacodynamic mechanism where CBD and clobazam together enhanced inhibitory GABAA receptor activation. SIGNIFICANCE Our study highlights the involvement of both pharmacodynamic and pharmacokinetic interactions between CBD and clobazam that may contribute to its efficacy in Dravet syndrome.
Collapse
Affiliation(s)
- Lyndsey L. Anderson
- Brain and Mind CentreThe University of SydneySydneyNew South WalesAustralia
- Discipline of PharmacologyFaculty of Medicine and HealthThe University of SydneySydneyNew South WalesAustralia
- Lambert Initiative for Cannabinoid TherapeuticsThe University of SydneySydneyNew South WalesAustralia
| | - Nathan L. Absalom
- Lambert Initiative for Cannabinoid TherapeuticsThe University of SydneySydneyNew South WalesAustralia
- School of PharmacyFaculty of Medicine and HealthThe University of SydneySydneyNew South WalesAustralia
| | - Sarah V. Abelev
- Discipline of PharmacologyFaculty of Medicine and HealthThe University of SydneySydneyNew South WalesAustralia
| | - Ivan K. Low
- Lambert Initiative for Cannabinoid TherapeuticsThe University of SydneySydneyNew South WalesAustralia
| | - Peter T. Doohan
- Discipline of PharmacologyFaculty of Medicine and HealthThe University of SydneySydneyNew South WalesAustralia
| | - Lewis J. Martin
- Brain and Mind CentreThe University of SydneySydneyNew South WalesAustralia
- Lambert Initiative for Cannabinoid TherapeuticsThe University of SydneySydneyNew South WalesAustralia
| | - Mary Chebib
- Brain and Mind CentreThe University of SydneySydneyNew South WalesAustralia
- School of PharmacyFaculty of Medicine and HealthThe University of SydneySydneyNew South WalesAustralia
| | - Iain S. McGregor
- Brain and Mind CentreThe University of SydneySydneyNew South WalesAustralia
- Lambert Initiative for Cannabinoid TherapeuticsThe University of SydneySydneyNew South WalesAustralia
- School of PsychologyFaculty of ScienceThe University of SydneySydneyNew South WalesAustralia
| | - Jonathon C. Arnold
- Brain and Mind CentreThe University of SydneySydneyNew South WalesAustralia
- Discipline of PharmacologyFaculty of Medicine and HealthThe University of SydneySydneyNew South WalesAustralia
- Lambert Initiative for Cannabinoid TherapeuticsThe University of SydneySydneyNew South WalesAustralia
| |
Collapse
|
5
|
Liao VWY, Chua HC, Kowal NM, Chebib M, Balle T, Ahring PK. Concatenated γ-aminobutyric acid type A receptors revisited: Finding order in chaos. J Gen Physiol 2019; 151:798-819. [PMID: 30988061 PMCID: PMC6572006 DOI: 10.1085/jgp.201812133] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/25/2018] [Accepted: 03/20/2019] [Indexed: 12/19/2022] Open
Abstract
Subunit concatenation is a powerful technique used to control the assembly of structurally diverse heteromeric receptors such as GABAARs. Liao et al. find that existing GABAAR concatemers do not assemble as expected and describe refinements that allow expression of uniform receptor populations. γ-aminobutyric acid type A receptors (GABAARs), the major inhibitory neurotransmitter receptors in the mammalian central nervous system, are arguably the most challenging member of the pentameric Cys-loop receptors to study due to their heteromeric structure. When two or more subunits are expressed together in heterologous systems, receptors of variable subunit type, ratio, and orientation can form, precluding accurate interpretation of data from functional studies. Subunit concatenation is a technique that involves the linking of individual subunits and in theory allows the precise control of the uniformity of expressed receptors. In reality, the resulting concatemers from widely used constructs are flexible in their orientation and may therefore assemble with themselves or free GABAAR subunits in unexpected ways. In this study, we examine functional responses of receptors from existing concatenated constructs and describe refinements necessary to allow expression of uniform receptor populations. We find that dimers from two commonly used concatenated constructs, β-23-α and α-10-β, assemble readily in both the clockwise and the counterclockwise orientations when coexpressed with free subunits. Furthermore, we show that concatemers formed from new tetrameric α-10-β-α-β and α-10-β-α-γ constructs also assemble in both orientations with free subunits to give canonical αβγ receptors. To restrict linker flexibility, we systematically shorten linker lengths of dimeric and pentameric constructs and find optimized constructs that direct the assembly of GABAARs only in one orientation, thus eliminating the ambiguity associated with previously described concatemers. Based on our data, we revisit some noncanonical GABAAR configurations proposed in recent years and explain how the use of some concatenated constructs may have led to wrong conclusions. Our results help clarify current contradictions in the literature regarding GABAAR subunit stoichiometry and arrangement. The lessons learned from this study may guide future efforts in understanding other related heteromeric receptors.
Collapse
Affiliation(s)
- Vivian Wan Yu Liao
- The University of Sydney, Brain and Mind Centre, School of Pharmacy, Faculty of Medicine and Health, Camperdown, New South Wales, Australia
| | - Han Chow Chua
- The University of Sydney, Brain and Mind Centre, School of Pharmacy, Faculty of Medicine and Health, Camperdown, New South Wales, Australia
| | - Natalia Magdalena Kowal
- The University of Sydney, Brain and Mind Centre, School of Pharmacy, Faculty of Medicine and Health, Camperdown, New South Wales, Australia.,Faculty of Pharmaceutical Sciences, School of Health Sciences, University of Iceland, Reykjavik, Iceland
| | - Mary Chebib
- The University of Sydney, Brain and Mind Centre, School of Pharmacy, Faculty of Medicine and Health, Camperdown, New South Wales, Australia
| | - Thomas Balle
- The University of Sydney, Brain and Mind Centre, School of Pharmacy, Faculty of Medicine and Health, Camperdown, New South Wales, Australia
| | - Philip Kiær Ahring
- The University of Sydney, Brain and Mind Centre, School of Pharmacy, Faculty of Medicine and Health, Camperdown, New South Wales, Australia
| |
Collapse
|
6
|
Absalom NL, Ahring PK, Liao VW, Balle T, Jiang T, Anderson LL, Arnold JC, McGregor IS, Bowen MT, Chebib M. Functional genomics of epilepsy-associated mutations in the GABA A receptor subunits reveal that one mutation impairs function and two are catastrophic. J Biol Chem 2019; 294:6157-6171. [PMID: 30728247 DOI: 10.1074/jbc.ra118.005697] [Citation(s) in RCA: 18] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/03/2018] [Revised: 01/30/2019] [Indexed: 12/29/2022] Open
Abstract
A number of epilepsy-causing mutations have recently been identified in the genes of the α1, β3, and γ2 subunits comprising the γ-aminobutyric acid type A (GABAA) receptor. These mutations are typically dominant, and in certain cases, such as the α1 and β3 subunits, they may lead to a mix of receptors at the cell surface that contain no mutant subunits, a single mutated subunit, or two mutated subunits. To determine the effects of mutations in a single subunit or in two subunits on receptor activation, we created a concatenated protein assembly that links all five subunits of the α1β3γ2 receptor and expresses them in the correct orientation. We created nine separate receptor variants with a single-mutant subunit and four receptors containing two subunits of the γ2R323Q, β3D120N, β3T157M, β3Y302C, and β3S254F epilepsy-causing mutations. We found that the singly mutated γ2R323Q subunit impairs GABA activation of the receptor by reducing GABA potency. A single β3D120N, β3T157M, or β3Y302C mutation also substantially impaired receptor activation, and two copies of these mutants within a receptor were catastrophic. Of note, an effect of the β3S254F mutation on GABA potency depended on the location of this mutant subunit within the receptor, possibly because of the membrane environment surrounding the transmembrane region of the receptor. Our results highlight that precise functional genomic analyses of GABAA receptor mutations using concatenated constructs can identify receptors with an intermediate phenotype that contribute to epileptic phenotypes and that are potential drug targets for precision medicine approaches.
Collapse
Affiliation(s)
- Nathan L Absalom
- From the Brain and Mind Centre, University of Sydney, 94 Mallett Street, Camperdown, New South Wales 2050, Australia; School of Pharmacy, University of Sydney, Camperdown, New South Wales 2006, Australia
| | - Philip K Ahring
- From the Brain and Mind Centre, University of Sydney, 94 Mallett Street, Camperdown, New South Wales 2050, Australia; School of Pharmacy, University of Sydney, Camperdown, New South Wales 2006, Australia
| | - Vivian W Liao
- From the Brain and Mind Centre, University of Sydney, 94 Mallett Street, Camperdown, New South Wales 2050, Australia; School of Pharmacy, University of Sydney, Camperdown, New South Wales 2006, Australia
| | - Thomas Balle
- From the Brain and Mind Centre, University of Sydney, 94 Mallett Street, Camperdown, New South Wales 2050, Australia; School of Pharmacy, University of Sydney, Camperdown, New South Wales 2006, Australia
| | - Tian Jiang
- From the Brain and Mind Centre, University of Sydney, 94 Mallett Street, Camperdown, New South Wales 2050, Australia; School of Pharmacy, University of Sydney, Camperdown, New South Wales 2006, Australia
| | - Lyndsey L Anderson
- From the Brain and Mind Centre, University of Sydney, 94 Mallett Street, Camperdown, New South Wales 2050, Australia; Discipline of Pharmacology, Faculty of Medicine and Health, University of Sydney, Camperdown, New South Wales 2006, Australia; Lambert Initiative for Cannabinoid Therapeutics, University of Sydney, 94 Mallett Street, Camperdown, New South Wales 2050, Australia
| | - Jonathon C Arnold
- From the Brain and Mind Centre, University of Sydney, 94 Mallett Street, Camperdown, New South Wales 2050, Australia; Discipline of Pharmacology, Faculty of Medicine and Health, University of Sydney, Camperdown, New South Wales 2006, Australia; Lambert Initiative for Cannabinoid Therapeutics, University of Sydney, 94 Mallett Street, Camperdown, New South Wales 2050, Australia
| | - Iain S McGregor
- From the Brain and Mind Centre, University of Sydney, 94 Mallett Street, Camperdown, New South Wales 2050, Australia; Lambert Initiative for Cannabinoid Therapeutics, University of Sydney, 94 Mallett Street, Camperdown, New South Wales 2050, Australia; the School of Psychology, Faculty of Science, University of Sydney, Camperdown, New South Wales 2006, Australia
| | - Michael T Bowen
- From the Brain and Mind Centre, University of Sydney, 94 Mallett Street, Camperdown, New South Wales 2050, Australia; Lambert Initiative for Cannabinoid Therapeutics, University of Sydney, 94 Mallett Street, Camperdown, New South Wales 2050, Australia; the School of Psychology, Faculty of Science, University of Sydney, Camperdown, New South Wales 2006, Australia
| | - Mary Chebib
- From the Brain and Mind Centre, University of Sydney, 94 Mallett Street, Camperdown, New South Wales 2050, Australia; School of Pharmacy, University of Sydney, Camperdown, New South Wales 2006, Australia.
| |
Collapse
|
7
|
Wongsamitkul N, Maldifassi MC, Simeone X, Baur R, Ernst M, Sigel E. α subunits in GABA A receptors are dispensable for GABA and diazepam action. Sci Rep 2017; 7:15498. [PMID: 29138471 PMCID: PMC5686171 DOI: 10.1038/s41598-017-15628-7] [Citation(s) in RCA: 29] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/17/2017] [Accepted: 10/31/2017] [Indexed: 11/10/2022] Open
Abstract
The major isoform of the GABAA receptor is α1β2γ2. The binding sites for the agonist GABA are located at the β2+/α1− subunit interfaces and the modulatory site for benzodiazepines at α1+/γ2−. In the absence of α1 subunits, a receptor was formed that was gated by GABA and modulated by diazepam similarly. This indicates that alternative subunits can take over the role of the α1 subunits. Point mutations were introduced in β2 or γ2 subunits at positions homologous to α1− benzodiazepine binding and GABA binding positions, respectively. From this mutation work we conclude that the site for GABA is located at a β2+/β2− subunit interface and that the diazepam site is located at the β2+/γ2− subunit interface. Computational docking leads to a structural hypothesis attributing this non-canonical interaction to a binding mode nearly identical with the one at the α1+/γ2− interface. Thus, the β2 subunit can take over the role of the α1 subunit for the formation of both sites, its minus side for the GABA binding site and its plus side for the diazepam binding site.
Collapse
Affiliation(s)
- Nisa Wongsamitkul
- Institute of Biochemistry and Molecular Medicine, University of Bern, Bern, Switzerland
| | - Maria C Maldifassi
- Institute of Biochemistry and Molecular Medicine, University of Bern, Bern, Switzerland.,Centro Interdisciplinario de Neurociencia de Valparaíso. Facultad de Ciencias, Universidad de Valparaíso, Valparaíso, Chile
| | - Xenia Simeone
- Department of Molecular Neurosciences, Center for Brain Research, Medical University of Vienna, Vienna, Austria
| | - Roland Baur
- Institute of Biochemistry and Molecular Medicine, University of Bern, Bern, Switzerland
| | - Margot Ernst
- Department of Molecular Neurosciences, Center for Brain Research, Medical University of Vienna, Vienna, Austria
| | - Erwin Sigel
- Institute of Biochemistry and Molecular Medicine, University of Bern, Bern, Switzerland.
| |
Collapse
|
8
|
Chua HC, Chebib M. GABA A Receptors and the Diversity in their Structure and Pharmacology. ADVANCES IN PHARMACOLOGY 2017; 79:1-34. [DOI: 10.1016/bs.apha.2017.03.003] [Citation(s) in RCA: 99] [Impact Index Per Article: 14.1] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/19/2022]
|
9
|
A pharmacological characterization of GABA, THIP and DS2 at binary α4β3 and β3δ receptors: GABA activates β3δ receptors via the β3(+)δ(−) interface. Brain Res 2016; 1644:222-30. [DOI: 10.1016/j.brainres.2016.05.019] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/03/2015] [Revised: 04/21/2016] [Accepted: 05/09/2016] [Indexed: 11/24/2022]
|
10
|
Zolpidem is a potent stoichiometry-selective modulator of α1β3 GABAA receptors: evidence of a novel benzodiazepine site in the α1-α1 interface. Sci Rep 2016; 6:28674. [PMID: 27346730 PMCID: PMC4921915 DOI: 10.1038/srep28674] [Citation(s) in RCA: 28] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/03/2016] [Accepted: 06/06/2016] [Indexed: 12/16/2022] Open
Abstract
Zolpidem is not a typical GABAA receptor hypnotic. Unlike benzodiazepines, zolpidem modulates tonic GABA currents in the rat dorsal motor nucleus of the vagus, exhibits residual effects in mice lacking the benzodiazepine binding site, and improves speech, cognitive and motor function in human patients with severe brain injury. The receptor by which zolpidem mediates these effects is not known. In this study we evaluated binary α1β3 GABAA receptors in either the 3α1:2β3 or 2α1:3β3 subunit stoichiometry, which differ by the existence of either an α1-α1 interface, or a β3-β3 interface, respectively. Both receptor stoichiometries are readily expressed in Xenopus oocytes, distinguished from each other by using GABA, zolpidem, diazepam and Zn2+. At the 3α1:2β3 receptor, clinically relevant concentrations of zolpidem enhanced GABA in a flumazenil-sensitive manner. The efficacy of diazepam was significantly lower compared to zolpidem. No modulation by either zolpidem or diazepam was detected at the 2α1:3β3 receptor, indicating that the binding site for zolpidem is at the α1-α1 interface, a site mimicking the classical α1-γ2 benzodiazepine site. Activating α1β3 (3α1:2β3) receptors may, in part, mediate the physiological effects of zolpidem observed under distinct physiological and clinical conditions, constituting a potentially attractive drug target.
Collapse
|
11
|
Chua HC, Christensen ETH, Hoestgaard-Jensen K, Hartiadi LY, Ramzan I, Jensen AA, Absalom NL, Chebib M. Kavain, the Major Constituent of the Anxiolytic Kava Extract, Potentiates GABAA Receptors: Functional Characteristics and Molecular Mechanism. PLoS One 2016; 11:e0157700. [PMID: 27332705 PMCID: PMC4917254 DOI: 10.1371/journal.pone.0157700] [Citation(s) in RCA: 50] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/24/2016] [Accepted: 05/31/2016] [Indexed: 11/19/2022] Open
Abstract
Extracts of the pepper plant kava (Piper methysticum) are effective in alleviating anxiety in clinical trials. Despite the long-standing therapeutic interest in kava, the molecular target(s) of the pharmacologically active constituents, kavalactones have not been established. γ-Aminobutyric acid type A receptors (GABAARs) are assumed to be the in vivo molecular target of kavalactones based on data from binding assays, but evidence in support of a direct interaction between kavalactones and GABAARs is scarce and equivocal. In this study, we characterised the functional properties of the major anxiolytic kavalactone, kavain at human recombinant α1β2, β2γ2L, αxβ2γ2L (x = 1, 2, 3 and 5), α1βxγ2L (x = 1, 2 and 3) and α4β2δ GABAARs expressed in Xenopus oocytes using the two-electrode voltage clamp technique. We found that kavain positively modulated all receptors regardless of the subunit composition, but the degree of enhancement was greater at α4β2δ than at α1β2γ2L GABAARs. The modulatory effect of kavain was unaffected by flumazenil, indicating that kavain did not enhance GABAARs via the classical benzodiazepine binding site. The β3N265M point mutation which has been previously shown to profoundly decrease anaesthetic sensitivity, also diminished kavain-mediated potentiation. To our knowledge, this study is the first report of the functional characteristics of a single kavalactone at distinct GABAAR subtypes, and presents the first experimental evidence in support of a direct interaction between a kavalactone and GABAARs.
Collapse
Affiliation(s)
- Han Chow Chua
- Faculty of Pharmacy, The University of Sydney, Sydney, New South Wales, Australia
| | - Emilie T. H. Christensen
- Faculty of Pharmacy, The University of Sydney, Sydney, New South Wales, Australia
- Department of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
| | - Kirsten Hoestgaard-Jensen
- Department of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
| | - Leonny Y. Hartiadi
- Faculty of Pharmacy, The University of Sydney, Sydney, New South Wales, Australia
| | - Iqbal Ramzan
- Faculty of Pharmacy, The University of Sydney, Sydney, New South Wales, Australia
| | - Anders A. Jensen
- Department of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
| | - Nathan L. Absalom
- Faculty of Pharmacy, The University of Sydney, Sydney, New South Wales, Australia
| | - Mary Chebib
- Faculty of Pharmacy, The University of Sydney, Sydney, New South Wales, Australia
- * E-mail:
| |
Collapse
|
12
|
High and low GABA sensitivity α4β2δ GABAA receptors are expressed in Xenopus laevis oocytes with divergent stoichiometries. Biochem Pharmacol 2016; 103:98-108. [DOI: 10.1016/j.bcp.2015.12.021] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/23/2015] [Accepted: 12/29/2015] [Indexed: 12/11/2022]
|